
ARCT
Arcturus Therapeutics Holdings Inc.
$21.03
+$0.57(+2.79%)
18
Overall
--
Value
18
Tech
--
Quality
Market Cap
$491.23M
Volume
682.32K
52W Range
$8.04 - $25.88
Target Price
$67.90
Order:
Income Statement
Metric | Trend | Chart | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
Total Revenue | $20.8M | $9.5M | $12.4M | $206.0M | $166.8M | $152.3M | ||
Total Revenue | $20.8M | $9.5M | $12.4M | $205.8M | $166.8M | $138.4M | ||
GROSS PROFIT | ||||||||
Gross Profit | $20.8M | $9.5M | $12.4M | $205.8M | $166.8M | $152.3M | ||
OPERATING EXPENSES | ||||||||
Operating Expenses | $46.3M | $81.1M | $215.2M | $193.6M | $245.0M | $248.0M | ||
Research & Development | $33.6M | $57.8M | $173.8M | $147.8M | $192.1M | $195.2M | ||
Research Expense | $33.6M | $57.8M | $173.8M | $147.8M | $192.1M | $195.2M | ||
Selling, General & Administrative | $12.7M | $23.2M | $41.5M | $46.1M | $52.9M | $52.8M | ||
General & Administrative Expenses | $12.7M | $23.2M | $41.5M | $46.1M | $52.9M | $52.8M | ||
Salaries & Wages | -- | -- | -- | $30.6M | $34.6M | $38.0M | ||
Depreciation & Amortization | $684.0K | $900.0K | $1.2M | $1.5M | $3.0M | $3.5M | ||
Depreciation & Amortization | $684.0K | $900.0K | $1.2M | $1.5M | $3.0M | $3.5M | ||
Other Operating Expenses | $1.2M | $-800.0K | $-1.0M | $-1.0M | $-600.0K | $-2.0M | ||
OPERATING INCOME | ||||||||
Operating income | $-25.5M | $-71.5M | $-202.9M | $12.2M | $-78.2M | $-95.7M | ||
EBITDA | $-24.4M | $-70.4M | $-201.7M | $15.2M | $-24.9M | $-77.4M | ||
NON-OPERATING ITEMS | ||||||||
Interest Expense (Non-Operating) | $900.0K | $831.0K | $2.7M | $3.0M | $767.0K | -- | ||
Net Non-Operating Interest Income/Expense | $-900.0K | $-900.0K | $-800.0K | $420.0K | $-16.6M | -- | ||
Other Income/Expense | $478.0K | $624.0K | $1.4M | $-1.1M | $-50.5M | $-15.2M | ||
Other Special Charges | $-446.0K | $-361.0K | $-1.9M | $-420.0K | $50.5M | $15.2M | ||
PRE-TAX INCOME | ||||||||
EBIT | $-25.1M | $-71.3M | $-202.9M | $13.6M | $-27.9M | $-80.9M | ||
Pre-Tax Income | $-26.0M | $-72.1M | $-203.7M | $10.6M | $-27.9M | $-80.9M | ||
INCOME TAX | ||||||||
Tax Provision | -- | -- | -- | $1.3M | $1.8M | $-4.0K | ||
NET INCOME | ||||||||
Net Income | $-26.0M | $-72.1M | $-203.7M | $9.3M | $-29.7M | $-80.9M | ||
Net Income (Continuing Operations) | $-26.0M | $-72.1M | $-203.7M | $9.3M | $-29.7M | $-80.9M | ||
Net Income (Discontinued Operations) | $-26.0M | $-72.1M | $-203.7M | $9.3M | $-29.7M | $-80.9M | ||
Net Income (Common Stockholders) | $-26.0M | $-72.1M | $-203.7M | $9.3M | $-29.7M | $-80.9M | ||
Normalized Income | -- | -- | -- | -- | -- | $-80.9M | ||
TOTALS | ||||||||
Total Expenses | $46.3M | $81.1M | $215.2M | $193.6M | $245.0M | $248.0M | ||
SHARE & EPS DATA | ||||||||
Average Shares Outstanding | $12.1M | $20.3M | $26.3M | $26.4M | $26.6M | $27.0M | ||
Average Shares Outstanding (Diluted) | $12.1M | $20.3M | $26.3M | $27.1M | $26.6M | $27.0M | ||
Shares Outstanding | $15.1M | $26.3M | $26.4M | $26.6M | $26.9M | $27.1M | ||
Basic EPS | $-2.15 | $-3.55 | $-7.74 | $0.35 | $-1.12 | $-3 | ||
Basic EPS (Continuing Operations) | $-2.15 | $-3.55 | $-7.74 | $0.35 | $-1.12 | $-3 | ||
Diluted EPS | $-2.15 | $-3.55 | $-7.74 | $0.35 | $-1.12 | $-3 | ||
Diluted EPS (Continuing Operations) | -- | -- | -- | $0.35 | $-1.12 | $-3 | ||
OTHER METRICS | ||||||||
Earnings from equity interest | $-32.0K | $-263.0K | $515.0K | $-515.0K | -- | -- | ||
Earnings From Equity Interest Net Of Tax | $-32.0K | $-263.0K | $515.0K | $-515.0K | -- | -- | ||
Other Gand A | $12.7M | $23.2M | $41.5M | $46.1M | $52.9M | $52.8M |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | ARCT | $21.03 | +2.8% | 682.32K |
3 | ||||
4 | ||||
5 | ||||
6 |
Get Arcturus Therapeutics Holdings Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW